Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Models of antidepressant action.

R M Berman1, D S Charney

  • 1Department of Psychiatry, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven 06519, USA. robert.berman@yale.edu

The Journal of Clinical Psychiatry
|July 17, 1999
PubMed
Summary

Current antidepressant treatments, primarily targeting monoamines, show limitations in explaining delayed response and incomplete efficacy. Future advancements require models extending beyond monoamines for better therapeutic outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome.

Translational psychiatry·2017
Same author

The MCP-4/MCP-1 ratio in plasma is a candidate circadian biomarker for chronic post-traumatic stress disorder.

Translational psychiatry·2017
Same author

Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.

Psychological medicine·2015
Same author

Serotonin versus catecholamine deficiency: behavioral and neural effects of experimental depletion in remitted depression.

Translational psychiatry·2015
Same author

Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder.

Translational psychiatry·2015
Same author

Developing cognitive-emotional training exercises as interventions for mood and anxiety disorders.

European psychiatry : the journal of the Association of European Psychiatrists·2014

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Decades of research have not fully elucidated the biological mechanisms behind antidepressant symptom relief.
  • Most antidepressant medications target monoamine neurotransmitters, forming the basis of current treatment models.

Purpose of the Study:

  • To review existing neurotransmitter, biochemical, and anatomic models of antidepressant action.
  • To assess the explanatory power and therapeutic applicability of these models.
  • To identify limitations in current models and suggest future research directions.

Main Methods:

  • Literature review of selected neurotransmitter, biochemical, and anatomic models.
  • Analysis of the explanatory power and therapeutic applicability of monoamine models.
  • Consideration of clinical limitations of current antidepressant treatments.

Main Results:

  • Monoamine models have guided therapeutic strategies but are incomplete.
  • These models fail to fully explain delayed response, incomplete efficacy, and unsustained remissions.
  • Current models do not adequately address critical biological mechanisms of symptom relief.

Conclusions:

  • Monoamine models are insufficient to explain all aspects of antidepressant action.
  • Further therapeutic advancements necessitate models that extend beyond the monoamine hypothesis.
  • Developing comprehensive models is crucial for overcoming current treatment limitations.

Related Experiment Videos